MCID: THR012
MIFTS: 51

Thoracic Cancer

Categories: Cancer diseases

Aliases & Classifications for Thoracic Cancer

MalaCards integrated aliases for Thoracic Cancer:

Name: Thoracic Cancer 12 55 15
Thoracic Neoplasms 44
Thorax Neoplasm 12
Tumor of Thorax 12
Thoracic Tumor 12
Thorax Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5093
ICD9CM 35 195.1
MeSH 44 D013899
NCIt 50 C3406 C3576
ICD10 33 C76.1
UMLS 72 C0039981 C0153661

Summaries for Thoracic Cancer

Disease Ontology : 12 An organ system cancer located in the thoracic cavity that develops in the different types of cells within the lungs, as well as less common cancers of the esophagus, the trachea, or the chest wall.

MalaCards based summary : Thoracic Cancer, also known as thoracic neoplasms, is related to breast cancer and soft tissue sarcoma. An important gene associated with Thoracic Cancer is CASP9 (Caspase 9), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Gemcitabine and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, trachea and testes, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Thoracic Cancer

Diseases related to Thoracic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 314)
# Related Disease Score Top Affiliating Genes
1 breast cancer 32.1 TP53 TNFSF10 PGR MUC1 ESR1 ERBB2
2 soft tissue sarcoma 31.3 TP53 EGFR BCL2
3 adenocarcinoma 31.1 TP53 MUC1 ERBB2 EGFR CDH1 AKT1
4 lung cancer 31.0 TP53 TNFSF10 ERBB2 EGFR CDKN1A CDH1
5 leiomyoma 31.0 PGR ESR1 CYP19A1
6 esophageal cancer 30.9 TP53 MUC1 ERBB2 EGFR CDKN1A CDH1
7 ewing sarcoma 30.8 TP53 TNFSF10 EGFR CDKN1A CDH1 CASP9
8 sarcoma, synovial 30.7 MUC1 CDH1 BCL2
9 lung squamous cell carcinoma 30.7 TP53 EGFR CDH1 AKT1
10 malignant peripheral nerve sheath tumor 30.6 TP53 MUC1 EGFR
11 lung cancer susceptibility 3 30.5 TP53 MUC1 ERBB2 EGFR CDKN1A CDH1
12 colorectal cancer 30.0 TP53 TNFSF10 MUC1 MIR342 ERBB2 EGFR
13 mediastinal cancer 11.4
14 smarca4-deficient sarcoma of thorax 11.1
15 chest wall lymphoma 11.1
16 hereditary site-specific ovarian cancer syndrome 11.1 BRCA2 BRCA1
17 glassy cell carcinoma of the cervix 11.1 PGR ESR1 ERBB2
18 male reproductive system disease 11.1 TP53 CDH1 AKT1
19 breast apocrine carcinoma 11.0 PGR ERBB2
20 tuberculous salpingitis 11.0 ERBB2 BRCA2 BRCA1
21 bartholin's gland adenoma 11.0 PGR ESR1
22 cancerophobia 11.0 PGR BRCA2 BRCA1
23 nosophobia 11.0 PGR BRCA2 BRCA1
24 scirrhous adenocarcinoma 11.0 PGR ERBB2
25 dystrophinopathies 11.0 TNFSF10 CASP9 CASP8 CASP6
26 breast intraductal proliferative lesion 11.0 ERBB2 EGFR
27 benign metastasizing leiomyoma 11.0 PGR CYP19A1 BCL2
28 vestibular gland benign neoplasm 11.0 PGR ESR1
29 progesterone-receptor negative breast cancer 11.0 PGR ERBB2 EGFR
30 endometrium carcinoma in situ 11.0 TP53 PGR
31 oncocytic breast carcinoma 11.0 PGR ESR1 EGFR
32 breast adenoid cystic carcinoma 11.0 PGR ESR1 ERBB2
33 fallopian tube adenocarcinoma 11.0 ERBB2 BRCA2 BRCA1
34 uterine corpus serous adenocarcinoma 11.0 TP53 ERBB2 BRCA1
35 myoma 11.0 PGR ESR1 CYP19A1
36 lung leiomyoma 11.0 PGR ESR1
37 vulvar syringoma 11.0 PGR ESR1
38 suppressor of tumorigenicity 3 11.0 TP53 CDKN1A BCL2
39 uterine body mixed cancer 11.0 TP53 PGR ERBB2
40 endometrial mucinous adenocarcinoma 11.0 PGR MUC1 ESR1
41 gender identity disorder 11.0 PGR ESR1 CYP19A1
42 breast squamous cell carcinoma 11.0 TP53 ERBB2 EGFR
43 papillary serous adenocarcinoma 11.0 TP53 PGR BRCA1
44 female reproductive endometrioid cancer 11.0 TP53 PGR ESR1
45 breast medullary carcinoma 11.0 PGR ESR1 ERBB2 BRCA1
46 cervical carcinosarcoma 11.0 TP53 PGR ESR1 BCL2
47 estrogen excess 11.0 PGR ESR1 CYP19A1
48 adenosarcoma 11.0 TP53 PGR ESR1
49 mammographic density 11.0 PGR ESR1 CYP19A1
50 progesterone-receptor positive breast cancer 11.0 PGR ESR1 ERBB2 CYP19A1

Graphical network of the top 20 diseases related to Thoracic Cancer:



Diseases related to Thoracic Cancer

Symptoms & Phenotypes for Thoracic Cancer

GenomeRNAi Phenotypes related to Thoracic Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.89 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.89 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
3 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 BCL2 BRCA1 BRCA2 CASP8 CDKN1A TP53

MGI Mouse Phenotypes related to Thoracic Cancer:

46 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 AKT1 BCL2 BRCA1 BRCA2 CASP6 CASP8
2 cardiovascular system MP:0005385 10.46 AKT1 BCL2 BRCA1 CASP8 CASP9 CDH1
3 endocrine/exocrine gland MP:0005379 10.46 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
4 homeostasis/metabolism MP:0005376 10.46 AKT1 BCL2 BRCA1 BRCA2 CASP6 CASP8
5 growth/size/body region MP:0005378 10.45 AKT1 BCL2 BRCA1 BRCA2 CASP6 CASP8
6 immune system MP:0005387 10.42 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
7 hematopoietic system MP:0005397 10.41 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
8 embryo MP:0005380 10.4 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
9 mortality/aging MP:0010768 10.37 AKT1 BCL2 BRCA1 BRCA2 CASP8 CASP9
10 behavior/neurological MP:0005386 10.36 AKT1 BCL2 BRCA1 BRCA2 CASP6 CDKN1A
11 integument MP:0010771 10.35 AKT1 BCL2 BRCA1 BRCA2 CASP8 CDH1
12 digestive/alimentary MP:0005381 10.3 BCL2 BRCA1 BRCA2 CDH1 CDKN1A CYP19A1
13 neoplasm MP:0002006 10.3 AKT1 BCL2 BRCA1 BRCA2 CASP8 CDH1
14 nervous system MP:0003631 10.25 AKT1 BCL2 BRCA1 BRCA2 CASP6 CASP8
15 adipose tissue MP:0005375 10.22 AKT1 BCL2 BRCA1 CDKN1A CYP19A1 EGFR
16 muscle MP:0005369 10.22 AKT1 BCL2 BRCA1 CASP8 CDKN1A CYP19A1
17 limbs/digits/tail MP:0005371 10.13 BRCA1 BRCA2 CDKN1A EGFR ERBB2 ESR1
18 liver/biliary system MP:0005370 10.11 AKT1 CASP8 CDKN1A CYP19A1 EGFR ESR1
19 normal MP:0002873 10.07 AKT1 BRCA1 BRCA2 CDH1 CYP19A1 EGFR
20 no phenotypic analysis MP:0003012 10.01 CASP6 CDH1 CDKN1A EGFR ESR1 KDM4C
21 reproductive system MP:0005389 9.93 AKT1 BCL2 BRCA1 BRCA2 CDH1 CDKN1A
22 renal/urinary system MP:0005367 9.86 BCL2 BRCA1 CASP8 CDKN1A CYP19A1 EGFR
23 pigmentation MP:0001186 9.72 BCL2 BRCA1 CYP19A1 EGFR TP53
24 respiratory system MP:0005388 9.61 AKT1 BRCA1 CASP8 CASP9 CDKN1A EGFR
25 skeleton MP:0005390 9.36 AKT1 BRCA1 BRCA2 CDKN1A CYP19A1 EGFR

Drugs & Therapeutics for Thoracic Cancer

Drugs for Thoracic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
3
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 60843 446556
4
leucovorin Approved Phase 3 58-05-9 143 6006
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9 Anti-Infective Agents Phase 3
10 Immunosuppressive Agents Phase 3
11 Antimetabolites Phase 3
12 Antiviral Agents Phase 3
13 Antimetabolites, Antineoplastic Phase 3
14 Folic Acid Antagonists Phase 3
15 Nucleic Acid Synthesis Inhibitors Phase 3
16 Vitamin B9 Phase 3
17 Folate Phase 3
18 Vitamin B Complex Phase 3
19 Protein Kinase Inhibitors Phase 3
20
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
21 Antibodies Phase 3
22 Immunoglobulins Phase 3
23 Immunologic Factors Phase 3
24 Antibodies, Monoclonal Phase 3
25 Antineoplastic Agents, Phytogenic Phase 3
26 Tubulin Modulators Phase 3
27 Albumin-Bound Paclitaxel Phase 3
28 Antimitotic Agents Phase 3
29
Durvalumab Approved, Investigational Phase 2 1428935-60-7
30
nivolumab Approved Phase 1, Phase 2 946414-94-4
31
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
32
Midazolam Approved, Illicit Phase 1, Phase 2 59467-70-8 4192
33
Budesonide Approved Phase 2 51333-22-3 63006 5281004
34
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
35
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
36 Cola Phase 1, Phase 2
37 Hormones Phase 2
38 Hormone Antagonists Phase 2
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
40 Anti-Inflammatory Agents Phase 2
41 Respiratory System Agents Phase 2
42 glucocorticoids Phase 2
43 Anti-Asthmatic Agents Phase 2
44 Autonomic Agents Phase 2
45 Peripheral Nervous System Agents Phase 2
46 Bronchodilator Agents Phase 2
47 Imatinib Mesylate Phase 2 220127-57-1 123596
48
Apatinib Phase 2 811803-05-1
49 glutamine Phase 1, Phase 2
50
Azacitidine Approved, Investigational Phase 1 320-67-2 9444

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care: The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I Recruiting NCT02845479 Phase 4
2 A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection(Dulanermin for Injection)in the Treatment of Advanced Non-small Cell Lung Cancer Unknown status NCT03083743 Phase 3
3 A Randomized, Controlled Phase III Trial to Evaluate the Efficacy of Elortinib vs Gefitinib in Advanced Non-small-cell Lung Cancer With EGFR Exon 19 or 21 Mutations Completed NCT01024413 Phase 3 erlotinib;gefitinib
4 Phase III Comparison of Postoperative 3D Conform Radiotherapy After Chemotherapy and Chemotherapy Alone in Patients With Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer Recruiting NCT00880971 Phase 3
5 A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Recruiting NCT03134872 Phase 3 Carboplatin;Pemetrexed
6 Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Recruiting NCT03402048 Phase 3 Carboplatin;Gemcitabine;Pemetrexed;Docetaxel;Vinorelbine
7 Comparison Study of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal Vedio-assisted Thoracic Surgery for Radical Lung Cancer Resection Recruiting NCT03331588 Phase 3
8 Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS:A Randomized Controlled Trial Recruiting NCT03521986 Phase 3
9 A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer Terminated NCT02826161 Phase 3 Napabucasin;Paclitaxel
10 Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy Terminated NCT02134015 Phase 3 Patritumab;Erlotinib;Placebo
11 A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162) Completed NCT01039948 Phase 1, Phase 2 Gefitinib
12 The Use of Multiple Respiration-Correlated Cone Beam CT Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer. Completed NCT00722605 Phase 1, Phase 2
13 A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer Completed NCT00983307 Phase 2 Erlotinib
14 Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer :A Multicenter,Randomized,Controlled,Phase 2 Study. Recruiting NCT03119519 Phase 2 No Local Definitive Radiotherapy
15 A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC) Recruiting NCT02904954 Phase 2 Durvalumab
16 A Safety and Efficacy Study of CT-Guided Adaptive Radiation Therapy With Anti-PD-1 Antibody Adjuvant Immunotherapy in Patients With Thoracic Cancer (CARTAI) Recruiting NCT03732430 Phase 2 IBI308
17 A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors With Specific Genomic Aberrations Recruiting NCT03989115 Phase 1, Phase 2 RMC-4630;Cobimetinib
18 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
19 A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors Recruiting NCT03899792 Phase 1, Phase 2 LOXO-292
20 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
21 A Feasibility and Biomarker Study to Evaluate Necitumumab in the Neoadjuvant Setting With Gemcitabine and Cisplatin in Surgically Resectable Squamous Lung Cancer Recruiting NCT03574818 Phase 2 Necitumumab-Gemcitabine-Cisplatin
22 A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1) Recruiting NCT03093116 Phase 1, Phase 2 Oral repotrectinib (TPX-0005)
23 A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001) Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
24 Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Non-small Cell Lung Cancer Patients Recruiting NCT03803787 Phase 2 Inhaled budesonide
25 A Randomized, Controlled Phase II Clinical Trial of Apatinib in Combination With EGFR-TKI Versus EGFR-TKI for Non-squamous, Non-small Cell Lung Cancer(NSCLC) With T790M-negative After the Failure of EGFR-TKI Therapy Not yet recruiting NCT03389256 Phase 2 Apatinib;EGFR-TKI
26 Phase II Study to Evaluate the Efficacy and Safety of Atezolizumab in Subjects With Unresectable or Advanced Malignant Pleural Mesothelioma Who Experienced Progression on Platinum-Based Chemotherapy Not yet recruiting NCT03786419 Phase 2 Atezolizumab
27 The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer With Radiation With or Without Chemotherapy Terminated NCT02575391 Phase 1, Phase 2
28 A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Withdrawn NCT02941601 Phase 2 Necitumumab;Gemcitabine;Carboplatin
29 Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC Unknown status NCT02009436 Phase 1 Azacitidine
30 STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors Completed NCT01639911 Phase 1 Alisertib;Pazopanib
31 A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer Completed NCT00437372 Phase 1 Sunitinib
32 Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies Completed NCT02264886 Phase 1
33 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
34 Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC) Completed NCT01999985 Phase 1 Dasatinib - 1A;Afatinib - 1A;Dasatinib - 1B;Afatinib - 1B
35 A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer and Men and Women With Progressive Non-Small Cell Lung Cancer Completed NCT01594398 Phase 1 entinostat;entinostat;Erlotinib;Erlotinib;Exemestane;Exemestane
36 A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors Recruiting NCT03634982 Phase 1 RMC-4630
37 A Pilot Study of FDG-PET Variability to Establish Biology-Guided Treatment Planning Feasibility for Stereotactic Body Radiation Therapy Recruiting NCT03493789 Phase 1 Fludeoxyglucose F-18
38 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
39 Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours Recruiting NCT02587455 Phase 1 Pembrolizumab
40 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Active, not recruiting NCT02909452 Phase 1 Entinostat;Pembrolizumab
41 A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy Active, not recruiting NCT02111824 Phase 1 Indocyanine Green (ICG)
42 Intratumoral Genetic Therapy for Lung Cancer Terminated NCT01574222 Phase 1
43 Prospect Study to Evaluate Clinical, Dosimetrical, Functional, Biological and Genetic Factors in Predicting Chemo-Radiotherapy Induced Lung and Esophagus Injury Unknown status NCT00631839
44 Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan: Correlation Between Radiotherapy Dose Distribution, Myocardial Perfusion, Cardiac Function, Serum Biomarkers and Clinical Prognosis. Unknown status NCT01913769
45 SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access Unknown status NCT02214134
46 Oncologic Therapy Support Via Means of a Dedicated Mobile App - a Prospective Feasibility Evaluation Unknown status NCT03168048
47 Assessment of Postoperative Lymphopenia as Risk Factor for Postoperative Infections: EVALYMPH Study Unknown status NCT02799251
48 Development and Feasibility of a Lung Cancer Nurse Model During Early Treatment: a Phase II Study Unknown status NCT02362204
49 Efficacy and Feasibility of a Psychosocial Intervention Within the CCOP Context: Evaluation of the Facing Forward Guide to Facilitate Life After Active Cancer Treatment Unknown status NCT00372840
50 Radiotherapeutic Tumor Response and Normal Tissue Effect in Treating Thoracic Malignancy : as Comparing With Free-breathing Non-gating Methods. Unknown status NCT02063633

Search NIH Clinical Center for Thoracic Cancer

Cochrane evidence based reviews: thoracic neoplasms

Genetic Tests for Thoracic Cancer

Anatomical Context for Thoracic Cancer

MalaCards organs/tissues related to Thoracic Cancer:

41
Lung, Trachea, Testes, Thyroid, Endothelial, Breast, Heart

The Foundational Model of Anatomy Ontology organs/tissues related to Thoracic Cancer:

19
Thoracic Cavity

Publications for Thoracic Cancer

Articles related to Thoracic Cancer:

(show top 50) (show all 200)
# Title Authors PMID Year
1
Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C). 9 38
15632825 2005
2
Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer. 38
30690684 2019
3
Effect of complementary Integrative Oncology on anxiety, depression and quality of life in thoracic cancer patients: A pilot study. 38
31383444 2019
4
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial. 38
31278102 2019
5
AAR-RT - A system for auto-contouring organs at risk on CT images for radiation therapy planning: Principles, design, and large-scale evaluation on head-and-neck and thoracic cancer cases. 38
30831357 2019
6
Technical Note: Density correction to improve CT number mapping in thoracic deformable image registration. 38
30896047 2019
7
Efficacy and tolerance of thoracic radiotherapy in the oldest old patients: A case series. 38
31062737 2019
8
Efficacy of radiofrequency ablation and microwave ablation in the treatment of thoracic cancer: A systematic review and meta-analysis. 38
30677240 2019
9
Holistic Needs of People with Thoracic Cancer Identified by the Sheffield Profile for Assessment and Referral to Care Questionnaire©. 38
30848688 2019
10
Radiosensitivity nomogram based on circulating neutrophils in thoracic cancer. 38
30693787 2019
11
Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. 38
30498004 2019
12
A longitudinal study of muscle strength and function in patients with cancer cachexia. 38
29860710 2019
13
PACE: A Probabilistic Atlas for Normal Tissue Complication Estimation in Radiation Oncology. 38
30918837 2019
14
Haplodeletion of Follistatin-Like 1 Attenuates Radiation-Induced Pulmonary Fibrosis in Mice. 38
30171878 2019
15
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. 38
30544524 2018
16
Thalidomide (THD) alleviates radiation induced lung fibrosis (RILF) via down-regulation of TGF-β/Smad3 signaling pathway in an Nrf2-dependent manner. 38
30339882 2018
17
Radiotherapy in palliation of thoracic tumors: a phase I-II study (SHARON project). 38
30298381 2018
18
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort. 38
30138763 2018
19
Physician Empathy Interacts with Breaking Bad News in Predicting Lung Cancer and Pleural Mesothelioma Patient Survival: Timing May Be Crucial. 38
30336582 2018
20
[Perioperative Venous Thromboembolism (VTE) Prophalaxis 
in Thoracic Cancer Patients: Chinese Experts Consensus]. 38
30309425 2018
21
Evaluation of a Dedicated Tobacco Cessation Support Service for Thoracic Cancer Center Patients. 38
29278577 2018
22
Naturopathic Oncology Care for Thoracic Cancers: A Practice Survey. 38
29558830 2018
23
Associations of Source-apportioned Fine Particles with Cause-specific Mortality in California. 38
29889687 2018
24
Within and between day repeatability of the incremental shuttle walking test in patients with thoracic cancer. 38
29957278 2018
25
Changing health behaviour with rehabilitation in thoracic cancer: A systematic review and synthesis. 38
29476566 2018
26
Development and evaluation of screening dysphagia tools for observational studies and routine care in cancer patients. 38
30623085 2018
27
Principal component analysis-based imaging angle determination for 3D motion monitoring using single-slice on-board imaging. 38
29635762 2018
28
The diagnostic value of tissue button technique for specimen accusation during endobronchial ultrasound-guided transbronchial fine-needle aspiration. 38
29124891 2018
29
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. 38
29346042 2018
30
Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. 38
29656758 2018
31
An Observational Study for Knowing the Compliance of Patients Scheduled for Major Abdominal and Thoracic Cancer Surgeries in a Single Specialty Center. 38
29962633 2018
32
Palliative Care Utilization among Patients Admitted for Gastrointestinal and Thoracic Cancers. 38
29100002 2018
33
A simple technique to improve calculated skin dose accuracy in a commercial treatment planning system. 38
29411506 2018
34
HSP27 inhibitor attenuates radiation-induced pulmonary inflammation. 38
29520071 2018
35
Caprini Risk Model Decreases Venous Thromboembolism Rates in Thoracic Surgery Cancer Patients. 38
29397103 2018
36
Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. 38
29106810 2018
37
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. 38
29401004 2018
38
Image Quality and Segmentation. 38
30111903 2018
39
Technical Note: Solving the "Chinese postman problem" for effective contour deformation. 38
29178498 2018
40
Reirradiation of thoracic cancers with intensity modulated proton therapy. 38
28867546 2018
41
Association between Radiotherapy and Anatomic Severity of Coronary Artery Disease: A Propensity Score Matching Comparison Among Adult-Onset Thoracic Cancer Survivors. 38
30176665 2018
42
Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. 38
29343723 2018
43
Developing an integrated rehabilitation model for thoracic cancer services: views of patients, informal carers and clinicians. 38
30349735 2018
44
Evaluation of lung toxicity risk with computed tomography ventilation image for thoracic cancer patients. 38
30281625 2018
45
Impact of CT slice thickness on volume and dose evaluation during thoracic cancer radiotherapy. 38
30288099 2018
46
Atlas ranking and selection for automatic segmentation of the esophagus from CT scans. 38
29049027 2017
47
Azithromycin attenuates acute radiation-induced lung injury in mice. 38
29098024 2017
48
Hypertrophic osteoarthropathy in a young adult male from Berber, Sudan (2nd-3rd century CE). 38
28888393 2017
49
Ethyl pyruvate alleviates radiation-induced lung injury in mice. 38
28570981 2017
50
Scientific Advances in Thoracic Oncology 2016. 38
28579481 2017

Variations for Thoracic Cancer

Expression for Thoracic Cancer

Search GEO for disease gene expression data for Thoracic Cancer.

Pathways for Thoracic Cancer

Pathways related to Thoracic Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 TP53 TNFSF10 MUC1 ESR1 ERBB2 EGFR
2
Show member pathways
13.8 TP53 ESR1 ERBB2 EGFR CDKN1A BRCA2
3
Show member pathways
13.78 TP53 TNFSF10 ERBB2 EGFR CDKN1A CASP9
4
Show member pathways
13.64 TP53 TNFSF10 ERBB2 EGFR CDKN1A CDH1
5
Show member pathways
13.51 TP53 TNFSF10 ERBB2 EGFR CDKN1A CASP9
6
Show member pathways
13.43 TP53 MUC1 ERBB2 EGFR CDKN1A BCL2
7
Show member pathways
13.41 TNFSF10 ERBB2 EGFR CDH1 CASP9 CASP8
8
Show member pathways
13.08 TP53 EGFR CDKN1A CASP9 CASP8 BCL2
9
Show member pathways
13.05 TP53 TNFSF10 EGFR CDKN1A CASP9 CASP8
10
Show member pathways
13.05 TP53 ERBB2 EGFR CDKN1A CASP9 CASP8
11
Show member pathways
13.04 TP53 TNFSF10 EGFR CASP9 CASP8 CASP6
12
Show member pathways
12.91 TP53 ERBB2 EGFR CDKN1A CDH1 CASP9
13
Show member pathways
12.9 TP53 TNFSF10 CDKN1A CASP9 CASP8 CASP6
14 12.89 TP53 ERBB2 EGFR CASP9 CASP8 CASP6
15 12.87 TP53 ESR1 ERBB2 EGFR CDKN1A CDH1
16
Show member pathways
12.84 TP53 ERBB2 EGFR CDKN1A CASP9 AKT1
17
Show member pathways
12.83 TP53 ESR1 ERBB2 CDH1 CASP9 BCL2
18
Show member pathways
12.8 TP53 EGFR CASP9 CASP8 BCL2 AKT1
19
Show member pathways
12.75 TNFSF10 EGFR CASP9 CASP8 AKT1
20
Show member pathways
12.73 TNFSF10 CASP9 CASP8 CASP6 BCL2 AKT1
21
Show member pathways
12.73 TP53 PGR ESR1 ERBB2 EGFR CDKN1A
22
Show member pathways
12.72 TP53 ESR1 CDKN1A CASP9 CASP8 CASP6
23
Show member pathways
12.7 TP53 ERBB2 EGFR CDKN1A AKT1
24
Show member pathways
12.7 TP53 ERBB2 EGFR CDKN1A CASP9 BCL2
25
Show member pathways
12.7 TP53 ESR1 ERBB2 EGFR CDKN1A CDH1
26 12.62 TP53 MIR342 ERBB2 EGFR CDKN1A BRCA1
27
Show member pathways
12.5 TP53 CDKN1A CASP9 CASP8 BRCA1 BCL2
28
Show member pathways
12.47 ESR1 CASP9 BRCA1 AKT1
29
Show member pathways
12.46 TP53 CDKN1A CASP9 AKT1
30
Show member pathways
12.46 TP53 ERBB2 EGFR CASP9 CASP8 CASP6
31 12.42 TP53 ESR1 ERBB2 EGFR CDKN1A AKT1
32
Show member pathways
12.4 ESR1 ERBB2 EGFR AKT1
33
Show member pathways
12.39 CASP9 CASP8 CASP6 BCL2 AKT1
34
Show member pathways
12.38 TNFSF10 CASP9 CASP8 AKT1
35 12.38 TNFSF10 CASP9 CASP8 CASP6 BCL2
36
Show member pathways
12.34 CASP9 CASP8 BCL2 AKT1
37 12.32 CASP9 CASP8 BCL2 AKT1
38
Show member pathways
12.31 PGR ESR1 CDKN1A BRCA1
39 12.29 TP53 EGFR CDKN1A CDH1 CASP9 AKT1
40
Show member pathways
12.28 TP53 ERBB2 EGFR CDKN1A CASP9 BCL2
41
Show member pathways
12.26 CDKN1A CASP9 CASP8 CASP6 AKT1
42 12.23 CDH1 CASP9 CASP8 CASP6 BCL2
43
Show member pathways
12.22 ERBB2 EGFR CDKN1A AKT1
44 12.2 TP53 EGFR CDKN1A CASP6 BCL2
45
Show member pathways
12.19 TNFSF10 EGFR CDKN1A AKT1
46
Show member pathways
12.19 TNFSF10 EGFR CDKN1A CDH1 BRCA1 BCL2
47
Show member pathways
12.18 TP53 EGFR CASP9 CASP8 AKT1
48 12.18 TP53 ERBB2 EGFR CDKN1A CASP9 BCL2
49
Show member pathways
12.17 TP53 CASP9 CASP8 BCL2 AKT1
50
Show member pathways
12.16 CASP9 CASP8 CASP6 BCL2 AKT1

GO Terms for Thoracic Cancer

Cellular components related to Thoracic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 TP53 PGR KDM4C ESR1 CDKN1A CASP8
2 cytoplasm GO:0005737 9.83 TP53 PGR MUC1 ESR1 ERBB2 EGFR
3 nuclear chromatin GO:0000790 9.56 TP53 MUC1 KDM4C ESR1
4 protein-containing complex GO:0032991 9.32 TP53 ESR1 EGFR CDKN1A CASP9 CASP8
5 nucleus GO:0005634 10.17 TP53 PGR MUC1 KDM4C ESR1 ERBB2

Biological processes related to Thoracic Cancer according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.98 TP53 EGFR CDKN1A BCL2 AKT1
2 cytokine-mediated signaling pathway GO:0019221 9.95 TP53 MUC1 CDKN1A BCL2 AKT1
3 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 ESR1 EGFR CDH1 BRCA2 BRCA1
4 cellular response to DNA damage stimulus GO:0006974 9.87 TP53 CDKN1A CASP9 BRCA2 BRCA1 BCL2
5 apoptotic process GO:0006915 9.86 TP53 TNFSF10 CASP9 CASP8 CASP6 BRCA1
6 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.85 TNFSF10 CASP9 CASP8
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 EGFR BCL2 AKT1
8 cellular response to mechanical stimulus GO:0071260 9.83 EGFR CASP8 AKT1
9 cell proliferation GO:0008283 9.83 TP53 EGFR BRCA2 BCL2 AKT1
10 cellular response to organic cyclic compound GO:0071407 9.82 CASP9 CASP8 AKT1
11 cellular response to growth factor stimulus GO:0071363 9.81 ERBB2 EGFR AKT1
12 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.81 TP53 MUC1 CDKN1A
13 positive regulation of fibroblast proliferation GO:0048146 9.79 ESR1 EGFR CDKN1A
14 cellular response to epidermal growth factor stimulus GO:0071364 9.77 ERBB2 EGFR AKT1
15 positive regulation of cell growth GO:0030307 9.76 ERBB2 EGFR BCL2 AKT1
16 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.73 TNFSF10 CASP8 BRCA1
17 response to antibiotic GO:0046677 9.71 TP53 CASP9 CASP8
18 response to gamma radiation GO:0010332 9.7 TP53 BRCA2 BCL2
19 cell aging GO:0007569 9.69 TP53 BRCA2 BCL2
20 replicative senescence GO:0090399 9.67 TP53 CDKN1A
21 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.67 TP53 CASP8 BCL2
22 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.67 CASP9 BRCA2 BRCA1 BCL2
23 regulation of mitochondrial membrane permeability GO:0046902 9.66 TP53 BCL2
24 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.66 TP53 ESR1
25 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 EGFR
26 execution phase of apoptosis GO:0097194 9.65 CASP8 CASP6 AKT1
27 response to cobalt ion GO:0032025 9.63 CASP9 CASP8
28 negative regulation of ERBB signaling pathway GO:1901185 9.62 ERBB2 EGFR
29 signal transduction by p53 class mediator GO:0072331 9.61 TP53 CDKN1A
30 cellular response to indole-3-methanol GO:0071681 9.61 CDH1 BRCA1
31 chordate embryonic development GO:0043009 9.59 BRCA2 BRCA1
32 mammary gland development GO:0030879 9.58 PGR CYP19A1
33 response to UV-A GO:0070141 9.57 EGFR AKT1
34 response to estradiol GO:0032355 9.46 ESR1 EGFR CASP9 CASP8
35 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 TP53 MUC1 BRCA2 BRCA1
36 regulation of apoptotic process GO:0042981 9.23 TP53 ESR1 CASP9 CASP8 CASP6 BRCA1
37 positive regulation of gene expression GO:0010628 10.04 TP53 KDM4C ERBB2 BRCA1 AKT1

Molecular functions related to Thoracic Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.95 TP53 TNFSF10 PGR KDM4C ESR1 BRCA1
2 protein kinase binding GO:0019901 9.88 TP53 ESR1 EGFR CDKN1A CASP9 AKT1
3 protein phosphatase binding GO:0019903 9.67 TP53 ERBB2 EGFR BCL2
4 ubiquitin protein ligase binding GO:0031625 9.63 TP53 EGFR CDKN1A CASP8 BRCA1 BCL2
5 protein phosphatase 2A binding GO:0051721 9.61 TP53 BCL2 AKT1
6 cysteine-type endopeptidase activity involved in apoptotic process GO:0097153 9.5 CASP9 CASP8 CASP6
7 enzyme binding GO:0019899 9.5 TP53 PGR KDM4C ESR1 EGFR BRCA1
8 cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097199 9.46 CASP9 CASP8
9 identical protein binding GO:0042802 9.44 TP53 TNFSF10 PGR ESR1 ERBB2 EGFR
10 nitric-oxide synthase regulator activity GO:0030235 9.43 ESR1 EGFR AKT1

Sources for Thoracic Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....